NEW YORK, Jan. 06, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ:AMLX) on behalf of Amylyx stockholders. Our investigation concerns whether Amylyx has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On November 9, 2023, Amylyx issued a press release announcing its third quarter ("Q3") 2023 results, including Q3 GAAP earnings-per-share of $0.30, missing consensus estimates by $0.12. The same day, Investor's Business Daily published an article entitled "Amylyx Crashes 27% As New ALS Drug Faces A Barrage Of Troubles". The article cited an ISI analyst, who questioned Amylyx's claim that the ...